Drug Profile
BMS 347070
Latest Information Update: 16 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer; Osteoarthritis; Pain
Most Recent Events
- 20 Feb 2004 No development reported - Phase-II for Colorectal cancer in USA (unspecified route)
- 20 Feb 2004 No development reported - Phase-II/III for Osteoarthritis in USA (unspecified route)
- 20 Feb 2004 No development reported - Phase-II/III for Pain in USA (unspecified route)